17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer

NCT00103272 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
74
Enrollment
NIH
Sponsor class

Conditions

Interventions

Sponsor

National Cancer Institute (NCI)